Drug Profile
Research programme: siglec-8 receptor antibodies
Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Johns Hopkins University School of Medicine
- Developer Allakos
- Class Antibodies
- Mechanism of Action Immunomodulators; Mast cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis; Inflammation
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for preclinical development in Fibrosis in USA
- 28 Oct 2018 No recent reports of development identified for preclinical development in Inflammation in USA
- 29 Nov 2016 Allakos in-licenses Siglec-8 receptor intellectual property from The Johns Hopkins University School of Medicine